Factor XIa Inhibitor Fails to Reduce Recurrent Cardiovascular Events After Acute Coronary Syndrome
Source Summary
An investigational factor XIa inhibitor did not reduce the risk of recurrent cardiovascular events in patients with recent acute coronary syndrome who were already receiving antiplatelet therapy. The drug showed no increase in adverse effects despite its lack of efficacy.
Why it matters
The trial result indicates this investigational drug does not provide additional cardiovascular protection beyond existing antiplatelet therapy for ACS patients.
